New data pushes the path of the mRNA cancer vaccine forward. The companies Moderna and Merck (MSD outside the United States and Canada) announced the results of the 3-year follow-up of melanoma patients treated with the experimental vaccine mRNA-4157 (V940) combined with immunotherapy Merck's pembrolizumab (Keytruda*) in a Phase 2b clinical trial. The combination has reduced the risk of recurrence or death by 49% and the risk of distant metastases or death by 62% compared to immunotherapy alone, at a median follow up of approximately 3 years. Data that highlights how the effects are continuing over time. The patients involved in the trial are patients with stage III/IV melanoma with a high risk of recurrence after complete resection.
Companies have initiated phase 3 trials as adjuvant treatment in patients with high-risk melanoma and lung cancer non-small cell and plan to rapidly expand to other tumor types.
#Melanoma #mRNA #anticancer #vaccine #halved #risk #death #years